Edgewise Therapeutics, Inc. (EWTX)
시가총액: 1.50B
국가: United States
산업: #Biotechnology_Pharmaceutical_Preparations
섹터: #Health_Care
홈페이지: https://www.edgewisetx.com

- 분기 매출(공시, 예측, 서프, YoY, QoQ)
2503: 0.00 / -- / -- / -- / --
2412: 0.00 / -- / -- / -- / --
2409: 0.00 / -- / -- / -- / --
2406: 0.00 / 0.00 / -- / -- / --
2403: 0.0 / -- / -- / -- / --

- 분기 EPS(공시, 예측, 서프, YoY, QoQ)
2503: -0.43 / -0.43 / 0.0% / -30.3% / -2.4%
2412: -0.42 / -0.42 / 0.0% / -- / -16.7%
2409: -0.36 / -0.37 / 2.7% / 12.2% / -5.9%
2406: -0.34 / -0.345 / 1.4% / 0.0% / -3.0%
2403: -0.33 / -- / -- / 8.3% / --

- 연간 매출(YoY%), EPS(YoY%)
2312: 0.0(--) / --(--)
2212: 0.0(--) / -1.26(-10.5%)
2112: 0.0(--) / -1.14(-210.0%)
2012: 0.0(--) / -0.367706(22.9%)

#EWTX

- 사업요약: Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, d...

Nuveen Churchill Direct Lending Corp. (NCDL)
시가총액: 852.93M
국가:
산업: None
섹터: None

- 분기 매출(공시, 예측, 서프, YoY, QoQ)
2503: 53.59M / -- / -- / 129.9% / -6.1%
2412: 57.08M / -- / -- / 89.7% / -5.3%
2409: 60.28M / -- / -- / 181.1% / 9.4%
2406: 55.09M / -- / -- / -- / 136.4%
2403: 23.31M / -- / -- / -8.2% / -22.5%

- 분기 EPS(공시, 예측, 서프, YoY, QoQ)
2503: 0.53 / 0.59 / -10.2% / -7.0% / -5.4%
2412: 0.56 / 0.57 / -1.8% / -- / -3.4%
2409: 0.58 / 0.56 / 3.6% / 57.8% / 56.8%
2406: 0.37 / 0.57 / -35.1% / -- / -35.1%
2403: 0.57 / -- / -- / 145.7% / --

- 연간 매출(YoY%), EPS(YoY%)
2312: 82.09M(67.4%) / 1.385332(339.3%)
2212: 49.03M(111.0%) / 0.315347(-36.6%)
2112: 23.23M(449.9%) / 0.497412(1171.1%)
2012: 4.22M(--) / 0.039131(--)

#NCDL

- 사업요약:

BlackRock TCP Capital Corp. (TCPC)
시가총액: 597.24M
국가: United States
산업: #Finance_Investors_Services
섹터: #Finance
홈페이지: https://www.tcpcapital.com

- 분기 매출(공시, 예측, 서프, YoY, QoQ)
2503: 55.89M / 63.94M / -12.6% / 544.3% / -8.8%
2412: 61.25M / 66.73M / -8.2% / 724.0% / -13.6%
2409: 70.93M / 66.49M / 6.7% / 389.9% / -0.8%
2406: 71.53M / 69.16M / 3.4% / 289.4% / 724.6%
2403: 8.67M / -- / -- / -66.3% / 188.4%

- 분기 EPS(공시, 예측, 서프, YoY, QoQ)
2503: 0.36 / 0.334 / 7.8% / 350.0% / 0.0%
2412: 0.36 / 0.37 / -2.7% / -- / 0.0%
2409: 0.36 / 0.39 / -7.7% / 63.6% / -5.3%
2406: 0.38 / 0.43 / -11.6% / 35.7% / 375.0%
2403: 0.08 / -- / -- / -79.5% / --

- 연간 매출(YoY%), EPS(YoY%)
2312: 50.67M(1707.7%) / --(--)
2212: 2.8M(-98.2%) / -0.16(-106.9%)
2112: 153.4M(76.2%) / 2.32(88.6%)
2012: 87.08M(--) / 1.23(136.5%)

#TCPC

- 사업요약: BlackRock TCP Capital Corp. is a business development company specializing in direct equity and debt investments in middle-market, small businesses, debt securities, senior secured loans, junio...

CION Investment Corporation (CION)
시가총액: 516.48M
국가: United States
산업: #Finance_Investors_Services
섹터: #Finance
홈페이지: https://www.cionbdc.com

- 분기 매출(공시, 예측, 서프, YoY, QoQ)
2503: 56.07M / 52.26M / 7.3% / 501.2% / -3.1%
2412: 57.89M / 54.11M / 7.0% / 7.8% / -2.9%
2409: 59.63M / 57.01M / 4.6% / 18.9% / -2.8%
2406: 61.36M / 57.59M / 6.5% / 98.0% / 557.9%
2403: 9.33M / -- / -- / 133.0% / -82.6%

- 분기 EPS(공시, 예측, 서프, YoY, QoQ)
2503: -0.8 / 0.3467 / -330.7% / -766.7% / -328.6%
2412: 0.35 / 0.35 / 0.0% / -62.8% / -12.5%
2409: 0.4 / 0.38 / 5.3% / -54.0% / -4.8%
2406: 0.42 / 0.39 / 7.7% / -17.6% / 250.0%
2403: 0.12 / -- / -- / 121.4% / -87.2%

- 연간 매출(YoY%), EPS(YoY%)
2312: 106.61M(74.4%) / 1.74(95.5%)
2212: 61.14M(-53.7%) / 0.89(-57.4%)
2112: 131.98M(6088.2%) / 2.09(1200.0%)
2012: -2204000.0(--) / -0.19(--)

#CION

- 사업요약: CION Investment Corporation is a business development company. It specializes in investments in senior secured loans, including unitranche loans, First Lien, second lien loans, lo...

Mind Medicine (MindMed) Inc. (MNMD)
시가총액: 488.82M
국가: United States
산업: #Medicinal_Chemicals_and_Botanical_Products
섹터: #Health_Care
홈페이지: https://www.mindmed.co

- 분기 매출(공시, 예측, 서프, YoY, QoQ)
2503: 0.00 / -- / -- / -- / --
2412: 0.00 / -- / -- / -- / --
2409: 0.00 / -- / -- / -- / --
2406: 0.00 / -- / -- / -- / --
2403: 0.0 / -- / -- / -- / --

- 분기 EPS(공시, 예측, 서프, YoY, QoQ)
2503: -0.35 / -0.34 / -2.9% / 69.3% / 14.6%
2412: -0.41 / -0.31 / -32.3% / -- / -51.9%
2409: -0.27 / -0.28 / 3.6% / 40.0% / -3.8%
2406: -0.26 / -0.33 / 21.2% / 65.8% / 77.2%
2403: -1.14 / -- / -- / -75.4% / --

- 연간 매출(YoY%), EPS(YoY%)
2312: 0.0(--) / -2.44(-32.6%)
2212: 0.0(--) / -1.84(45.9%)
2112: 0.0(--) / -3.4(-74.4%)
2012: 0.0(--) / -1.95(--)

#MNMD

- 사업요약: Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and at...

Amylyx Pharmaceuticals, Inc. (AMLX)
시가총액: 431.49M
국가: United States
산업: #Biotechnology_Pharmaceutical_Preparations
섹터: #Health_Care
홈페이지: https://amylyx.com

- 분기 매출(공시, 예측, 서프, YoY, QoQ)
2503: 0.00 / -- / -- / -100.0% / 100.0%
2412: -665K / -- / -- / -100.6% / -259.9%
2409: 416K / -- / -- / -99.6% / 140.8%
2406: -1.02M / 10.66M / -109.6% / -101.0% / -101.2%
2403: 88.64M / -- / -- / 24.1% / -18.3%

- 분기 EPS(공시, 예측, 서프, YoY, QoQ)
2503: -0.42 / -0.62 / 32.3% / 76.0% / 23.6%
2412: -0.55 / -0.56 / 1.8% / -885.7% / 48.6%
2409: -1.07 / -0.7 / -52.9% / -456.7% / 0.0%
2406: -1.07 / -0.73 / -46.6% / -445.2% / 38.9%
2403: -1.75 / -- / -- / -8850.0% / -2600.0%

- 연간 매출(YoY%), EPS(YoY%)
2312: 380.79M(1612.9%) / 0.7(120.6%)
2212: 22.23M(--) / -3.39(-112.9%)
2112: 0.0(--) / -1.592491(-73.1%)
2012: 0.0(--) / -0.920101(--)

#AMLX

- 사업요약: Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and n...

ProQR Therapeutics N.V. (PRQR)
시가총액: 159.40M
국가: Netherlands
산업: #Biotechnology_Pharmaceutical_Preparations
섹터: #Health_Care
홈페이지: https://www.proqr.com

- 분기 매출(공시, 예측, 서프, YoY, QoQ)
2503: 4.52M / 3.9M / 15.9% / 1.6% / 7.4%
2412: 4.21M / 6.57M / -35.9% / 28.2% / 9.6%
2409: 3.84M / 11.07M / -65.3% / 180.3% / -39.1%
2406: 6.31M / 11.46M / -44.9% / 423.7% / 41.8%
2403: 4.45M / -- / -- / 579.4% / 35.5%

- 분기 EPS(공시, 예측, 서프, YoY, QoQ)
2503: -0.1 / -0.0928 / -7.8% / -11.1% / -11.1%
2412: -0.09 / -0.0946 / 4.9% / -- / 10.0%
2409: -0.1 / -0.106 / 5.7% / -42.9% / -233.3%
2406: -0.03 / -0.1248 / 76.0% / 70.0% / 66.7%
2403: -0.09 / -- / -- / 18.2% / --

- 연간 매출(YoY%), EPS(YoY%)
2312: 6.51M(81.2%) / -0.35(61.1%)
2212: 3.59M(169.2%) / -0.9(5.3%)
2112: 1.33M(--) / -0.95(-2.2%)
2012: 0.0(--) / -0.93(--)

#PRQR

- 사업요약: ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic d...

RAPT Therapeutics, Inc. (RAPT)
시가총액: 106.93M
국가: United States
산업: #Biotechnology_Pharmaceutical_Preparations
섹터: #Health_Care
홈페이지: https://www.rapt.com

- 분기 매출(공시, 예측, 서프, YoY, QoQ)
2503: 0.00 / 0.00 / -- / -- / --
2412: 0.00 / 0.00 / -- / -- / --
2409: 0.00 / 0.00 / -- / -- / --
2406: 0.00 / 0.00 / -- / -- / --
2403: 0.0 / -- / -- / -- / --

- 분기 EPS(공시, 예측, 서프, YoY, QoQ)
2503: -0.08 / -0.1211 / 33.9% / 89.9% / 93.0%
2412: -1.14 / -0.32 / -256.2% / -- / -142.6%
2409: -0.47 / -0.56 / 16.1% / 42.7% / 33.8%
2406: -0.71 / -0.7203 / 1.4% / -7.6% / 10.1%
2403: -0.79 / -- / -- / -3.9% / --

- 연간 매출(YoY%), EPS(YoY%)
2312: 0.0(-100.0%) / --(--)
2212: 1.53M(-60.0%) / -2.58(-2.0%)
2112: 3.81M(-24.4%) / -2.53(-15.5%)
2012: 5.04M(--) / -2.19(77.9%)

#RAPT

- 사업요약: RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory disea...

Veru Inc. (VERU)
시가총액: 74.80M
국가: United States
산업: #Biotechnology_Pharmaceutical_Preparations
섹터: #Health_Care
홈페이지: https://verupharma.com

- 분기 매출(공시, 예측, 서프, YoY, QoQ)
2503: 0.00 / 580K / -100.0% / -100.0% / -100.0%
2412: 3.2M / 3M / 6.7% / 49.5% / -17.9%
2409: 3.9M / 3.56M / 9.6% / 1.0% / -1.3%
2406: 3.95M / 3.5M / 12.9% / 18.2% / -4.5%
2403: 4.14M / -- / -- / -37.2% / 93.2%

- 분기 EPS(공시, 예측, 서프, YoY, QoQ)
2503: -0.05 / -0.06 / 16.7% / 28.6% / 16.7%
2412: -0.06 / -0.08 / 25.0% / 25.0% / 20.0%
2409: -0.075 / -0.074 / -1.4% / -- / -7.1%
2406: -0.07 / -0.058 / -20.7% / 12.5% / 0.0%
2403: -0.07 / -- / -- / 83.3% / 12.5%

- 연간 매출(YoY%), EPS(YoY%)
2309: 16.3M(-58.6%) / -1.1(-4.8%)
2209: 39.35M(-35.8%) / -1.05(-1266.7%)
2109: 61.26M(43.8%) / 0.09(132.1%)
2009: 42.59M(--) / -0.28(--)

#VERU

- 사업요약: Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its markete...

Cadrenal Therapeutics, Inc. (CVKD)
시가총액: 30.59M
국가: United States
산업: #Biotechnology_Pharmaceutical_Preparations
섹터: #Health_Care
홈페이지: https://www.cadrenal.com

- 분기 매출(공시, 예측, 서프, YoY, QoQ)
2503: 0.00 / -- / -- / -- / --
2412: 0.00 / -- / -- / -- / --
2409: -- / -- / -- / -- / --
2406: 0.00 / -- / -- / -- / --
2403: 0.0 / -- / -- / -- / --

- 분기 EPS(공시, 예측, 서프, YoY, QoQ)
2503: -2.09 / -- / -- / -1990.0% / -21.5%
2412: -1.72 / -0.15 / -1046.7% / -- / --
2409: -- / -0.12 / -- / -- / --
2406: -0.085 / -0.12 / 29.2% / 5.6% / 15.0%
2403: -0.1 / -- / -- / 79.2% / --

- 연간 매출(YoY%), EPS(YoY%)

#CVKD

- 사업요약: Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney d...

ALX Oncology Holdings Inc. (ALXO)
시가총액: 25.10M
국가: United States
산업: #Biotechnology_Pharmaceutical_Preparations
섹터: #Health_Care
홈페이지: https://www.alxoncology.com

- 분기 매출(공시, 예측, 서프, YoY, QoQ)
2503: 0.00 / 0.00 / -- / -- / --
2412: 0.00 / -- / -- / -- / --
2409: 0.00 / 0.00 / -- / -- / --
2406: 0.00 / 0.00 / -- / -- / --
2403: 0.0 / -- / -- / -- / --

- 분기 EPS(공시, 예측, 서프, YoY, QoQ)
2503: -0.58 / -0.519 / -11.8% / 18.3% / -5.5%
2412: -0.55 / -0.67 / 17.9% / -- / 5.2%
2409: -0.58 / -0.78 / 25.6% / 53.2% / 23.7%
2406: -0.76 / -0.7397 / -2.7% / 9.5% / -7.0%
2403: -0.71 / -- / -- / 4.1% / --

- 연간 매출(YoY%), EPS(YoY%)
2312: 0.0(--) / --(--)
2212: 0.0(--) / -3.03(-46.4%)
2112: 0.0(-100.0%) / -2.07(25.0%)
2012: 1.18M(--) / -2.76(-160.3%)

#ALXO

- 사업요약: ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development a...